

## Cosentyx® (secukinumab) – New indication, expanded indication

- On December 23, 2021, <u>Novartis announced</u> the FDA approval of <u>Cosentyx (secukinumab)</u>, for the treatment of active enthesitis-related arthritis (ERA) in patients 4 years of age and older.
- In addition, the FDA approved Cosentyx for the treatment of active psoriatic arthritis (PsA) in patients 2 years of age and older.
  - Cosentyx was previously approved for this indication in adults only.
- Cosentyx is also approved for the treatment of:
  - Moderate to severe plaque psoriasis in patients 6 years and older who are candidates for systemic therapy or phototherapy
  - Adult patients with active ankylosing spondylitis
  - Adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation.
- The approval of Cosentyx for the new and expanded indications was based on a 3-part, randomized, double-blind, placebo-controlled, event-driven study in patients 2 to < 18 years of age with active ERA or juvenile psoriatic arthritis (JPsA). The study consisted of an open-label portion (Part 1) followed by randomized withdrawal (Part 2) followed by open-label treatment (Part 3). The primary endpoint was time to flare in Part 2. Disease flare was defined as a ≥ 30% worsening in at least three of the six JIA ACR response criteria and ≥ 30% improvement in not more than one of the six JIA ACR response criteria and a minimum of two active joints.
  - During Part 2, a total of 11 JPsA patients in the placebo group experienced a flare event compared with 4 JPsA patients in the Cosentyx group. The risk of flare was reduced by 85% for patients on Cosentyx vs. placebo (hazard ratio [HR] 0.15, 95% CI: 0.04 to 0.56).
  - During Part 2, a total of 10 ERA patients in the placebo group experienced a flare event compared with 6 ERA patients in the Cosentyx group. The risk of flare was reduced by 53% for patients on Cosentyx vs. placebo (HR 0.47, 95% CI: 0.17 to 1.32).
- For pediatric patients with PsA and ERA, the recommended dose of Cosentyx is based on body weight and administered by subcutaneous (SC) injection at weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter.
  - For patients weighing ≥ 15 kg and < 50 kg the recommended dose is 75 mg</p>
  - For patients weighing ≥ 50 kg the recommended dose is 150 mg.
- Refer to the Cosentyx drug label for dosing for all its other indications and uses.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

 $\mbox{RxNews}^{\mbox{\tiny @}}$  is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.